InflaRx Prices Underwritten Offering of 75M Shares at $2.00 Each
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 32 minutes ago
0mins
Should l Buy IFRX?
Source: seekingalpha
- Offering Pricing: InflaRx announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 per share, with all shares being sold by the company, indicating a proactive financing strategy in the capital markets.
- Clear Use of Proceeds: The net proceeds from this offering are intended to advance the company's pipeline activities and support working capital and general corporate purposes, reflecting the company's focus on future business development and prudent capital allocation.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance, with shares trading above $1, which helps enhance investor confidence and may attract more institutional investors' interest.
- Positive Market Response: InflaRx's presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference garnered market attention, and combined with its historical earnings data, may lay a foundation for the company's future stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IFRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IFRX
Wall Street analysts forecast IFRX stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 1.970
Low
6.00
Averages
12.67
High
24.00
Current: 1.970
Low
6.00
Averages
12.67
High
24.00
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
InflaRx N.V. Prices 75 Million Share Offering at $2.00 Each
- Offering Size and Pricing: InflaRx N.V. announced the pricing of its offering of 75 million ordinary shares at $2.00 per share, expected to close on May 7, 2026, which will provide crucial funding to advance its research pipeline.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for working capital, demonstrating the company's commitment to future product development and responsiveness to market demands.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, indicating strong market confidence in InflaRx and its appeal in the biopharmaceutical sector.
- Strong Underwriter Team: Guggenheim Securities is acting as the lead underwriter for the offering, with Oppenheimer & Co. and LifeSci Capital also involved, showcasing the company's robust support and expertise in capital markets.
See More
InflaRx Prices Underwritten Offering of 75M Shares at $2.00 Each
- Offering Pricing: InflaRx announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 per share, with all shares being sold by the company, indicating a proactive financing strategy in the capital markets.
- Clear Use of Proceeds: The net proceeds from this offering are intended to advance the company's pipeline activities and support working capital and general corporate purposes, reflecting the company's focus on future business development and prudent capital allocation.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance, with shares trading above $1, which helps enhance investor confidence and may attract more institutional investors' interest.
- Positive Market Response: InflaRx's presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference garnered market attention, and combined with its historical earnings data, may lay a foundation for the company's future stock performance.
See More
InflaRx Unveils New Pre-Clinical Data on Izicopan
- Low Reactive Metabolite Formation: InflaRx's new data indicates that izicopan exhibits low reactive metabolite formation in human liver microsomes, suggesting a reduced bioactivation-related safety risk, which could enhance its competitive position in the market.
- Comparison with Avacopan: In vitro studies reveal that izicopan's reactive metabolite formation is significantly lower than that of the marketed C5aR1 inhibitor avacopan, with peak areas differing by over 100-fold at early time points, indicating a potential safety advantage for izicopan.
- Pre-Clinical Research Results: Izicopan has demonstrated anti-inflammatory effects in several pre-clinical disease models and showed good tolerability in a Phase 1 study with a maximum dose of 240 mg, with no safety signals reported, highlighting its best-in-class potential.
- Significant Therapeutic Effects: In patients with hidradenitis suppurativa, izicopan led to substantial reductions in abscesses and nodules over four weeks, along with notable improvements in patient-reported pain scores, suggesting its potential for biologic-like efficacy.
See More
InflaRx to Release Q1 2026 Financial Results on May 7
- Earnings Announcement: InflaRx N.V. has announced that it will publish its financial and operational results for Q1 2026 on May 7, 2026, before the market opens, indicating the company's commitment to transparency despite not holding a conference call.
- Innovative Drug Development: The company focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, highlighting its potential in treating various inflammatory diseases.
- Technological Edge: InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity and tolerability in multiple studies, further solidifying its competitive position in the biopharmaceutical sector.
- Global Presence: With offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, InflaRx demonstrates a strategic expansion approach aimed at meeting the growing market demand through innovative therapies.
See More
InflaRx Regains Compliance with Nasdaq Minimum Bid Price
- Compliance Restored: InflaRx N.V. announced that its shares closed at or above $1.00 for 10 consecutive trading days from April 13 to April 24, thereby regaining compliance with Nasdaq's minimum bid price requirement, ensuring the company's continued operation in the capital markets.
- Nasdaq Confirmation: The company received written confirmation from Nasdaq on April 27 that the compliance issue has been resolved and closed, a development that is likely to boost investor confidence and positively impact the stock price.
- Anti-Inflammatory Therapy Development: InflaRx focuses on developing anti-inflammatory therapies targeting the complement system, with lead programs izicopan and vilobelimab currently in clinical development, which could lay the groundwork for future revenue growth if successful.
- Investor Engagement: InflaRx presented its latest developments at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, attracting investor interest and further enhancing the company's visibility and market recognition in the biopharmaceutical sector.
See More
InflaRx Regains Compliance with Nasdaq Listing Requirements
- Compliance Notification: InflaRx N.V. received a written notice from Nasdaq confirming its compliance with the minimum bid price requirement, indicating a restoration of the company's stability and compliance in the stock market.
- Stock Performance: The notice states that InflaRx's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive trading days from April 13 to April 24, 2026, which not only meets Nasdaq's requirements but also boosts investor confidence.
- Business Context: InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan showing promising pharmacokinetic and therapeutic potential in clinical studies, poised to play a significant role in treating various inflammatory diseases.
- Market Outlook: With the restoration of compliance, InflaRx can continue its R&D efforts, particularly in treating conditions like hidradenitis suppurativa, thereby enhancing its market competitiveness and driving business growth.
See More
InflaRx N.V. Prices 75 Million Share Offering at $2.00 Each
- Offering Size and Pricing: InflaRx N.V. announced the pricing of its offering of 75 million ordinary shares at $2.00 per share, expected to close on May 7, 2026, which will provide crucial funding to advance its research pipeline.
- Clear Use of Proceeds: The net proceeds from this offering will be utilized to advance the company's pipeline activities and for working capital, demonstrating the company's commitment to future product development and responsiveness to market demands.
- Investor Participation: The financing attracted participation from both new and existing investors, including TCGX and Farallon Capital, indicating strong market confidence in InflaRx and its appeal in the biopharmaceutical sector.
- Strong Underwriter Team: Guggenheim Securities is acting as the lead underwriter for the offering, with Oppenheimer & Co. and LifeSci Capital also involved, showcasing the company's robust support and expertise in capital markets.
See More
InflaRx Prices Underwritten Offering of 75M Shares at $2.00 Each
- Offering Pricing: InflaRx announced the pricing of its underwritten offering of 75 million ordinary shares at $2.00 per share, with all shares being sold by the company, indicating a proactive financing strategy in the capital markets.
- Clear Use of Proceeds: The net proceeds from this offering are intended to advance the company's pipeline activities and support working capital and general corporate purposes, reflecting the company's focus on future business development and prudent capital allocation.
- Compliance Restoration: InflaRx has recently regained Nasdaq compliance, with shares trading above $1, which helps enhance investor confidence and may attract more institutional investors' interest.
- Positive Market Response: InflaRx's presentation at Oppenheimer's 36th Annual Healthcare Life Sciences Conference garnered market attention, and combined with its historical earnings data, may lay a foundation for the company's future stock performance.
See More
InflaRx Unveils New Pre-Clinical Data on Izicopan
- Low Reactive Metabolite Formation: InflaRx's new data indicates that izicopan exhibits low reactive metabolite formation in human liver microsomes, suggesting a reduced bioactivation-related safety risk, which could enhance its competitive position in the market.
- Comparison with Avacopan: In vitro studies reveal that izicopan's reactive metabolite formation is significantly lower than that of the marketed C5aR1 inhibitor avacopan, with peak areas differing by over 100-fold at early time points, indicating a potential safety advantage for izicopan.
- Pre-Clinical Research Results: Izicopan has demonstrated anti-inflammatory effects in several pre-clinical disease models and showed good tolerability in a Phase 1 study with a maximum dose of 240 mg, with no safety signals reported, highlighting its best-in-class potential.
- Significant Therapeutic Effects: In patients with hidradenitis suppurativa, izicopan led to substantial reductions in abscesses and nodules over four weeks, along with notable improvements in patient-reported pain scores, suggesting its potential for biologic-like efficacy.
See More
InflaRx to Release Q1 2026 Financial Results on May 7
- Earnings Announcement: InflaRx N.V. has announced that it will publish its financial and operational results for Q1 2026 on May 7, 2026, before the market opens, indicating the company's commitment to transparency despite not holding a conference call.
- Innovative Drug Development: The company focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan demonstrating promising pharmacokinetic and pharmacodynamic characteristics in Phase 1 and Phase 2a clinical studies, highlighting its potential in treating various inflammatory diseases.
- Technological Edge: InflaRx has also developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity and tolerability in multiple studies, further solidifying its competitive position in the biopharmaceutical sector.
- Global Presence: With offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA, InflaRx demonstrates a strategic expansion approach aimed at meeting the growing market demand through innovative therapies.
See More
InflaRx Regains Compliance with Nasdaq Minimum Bid Price
- Compliance Restored: InflaRx N.V. announced that its shares closed at or above $1.00 for 10 consecutive trading days from April 13 to April 24, thereby regaining compliance with Nasdaq's minimum bid price requirement, ensuring the company's continued operation in the capital markets.
- Nasdaq Confirmation: The company received written confirmation from Nasdaq on April 27 that the compliance issue has been resolved and closed, a development that is likely to boost investor confidence and positively impact the stock price.
- Anti-Inflammatory Therapy Development: InflaRx focuses on developing anti-inflammatory therapies targeting the complement system, with lead programs izicopan and vilobelimab currently in clinical development, which could lay the groundwork for future revenue growth if successful.
- Investor Engagement: InflaRx presented its latest developments at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, attracting investor interest and further enhancing the company's visibility and market recognition in the biopharmaceutical sector.
See More
InflaRx Regains Compliance with Nasdaq Listing Requirements
- Compliance Notification: InflaRx N.V. received a written notice from Nasdaq confirming its compliance with the minimum bid price requirement, indicating a restoration of the company's stability and compliance in the stock market.
- Stock Performance: The notice states that InflaRx's ordinary shares maintained a closing bid price of $1.00 or greater for 10 consecutive trading days from April 13 to April 24, 2026, which not only meets Nasdaq's requirements but also boosts investor confidence.
- Business Context: InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, with its lead product izicopan showing promising pharmacokinetic and therapeutic potential in clinical studies, poised to play a significant role in treating various inflammatory diseases.
- Market Outlook: With the restoration of compliance, InflaRx can continue its R&D efforts, particularly in treating conditions like hidradenitis suppurativa, thereby enhancing its market competitiveness and driving business growth.
See More
